Published on:

Judge Andrews issues post-trial opinion in suit regarding ViiV Healthcare’s HIV drugs, finding patent valid and not infringed by Lupin

Today, Judge Richard G. Andrews issued a post-trial opinion in the litigation over ViiV Healthcare’s drugs for treating HIV infection, Trizivir and Epzicom. ViiV Healthcare UK Ltd., v. Lupin Ltd., C.A. No. 11-576-RGA (consol.) (D. Del. Dec. 17, 2013). Defendants Lupin and Teva sought FDA approval for generic versions of Trizivir and Epzicom, respectively. After a 4.5 day bench trial, Judge Andrews issued this post-trial opinion finding that defendants failed to prove invalidity and that ViiV failed to prove that Lupin’s generic drug infringed the asserted claims of the patent-in-suit, U.S. Patent No. 6,417,191.

ViiV Healthcare UK Ltd., v. Lupin Ltd., C.A. No. 11-576-RGA (consol.) (D. Del. Dec. 17, 2013)

Contact Information